Sex-Specific Effects of Prenatal Low-Protein and Carbenoxolone Exposure on Renal Angiotensin Receptor Expression in Rats

Sarah McMullen, Simon C. Langley-Evans

Abstract—Experimental models have shown the developing cardiovascular and renal systems to be sensitive to mild shifts in maternal nutrition, leading to altered function and risk of disease in adult life. The offspring of Wistar rats fed a low-protein diet during pregnancy exhibit a reduced nephron number and hypertension in postnatal life, providing a useful tool to examine the mechanistic basis of programming. Evidence indicates that upregulation of the renin-angiotensin system plays an important role, in particular through receptor-mediated changes in angiotensin II activity. However, although programmed hypertension has proven dependent on maternal glucocorticoids, there appear to be conflicting effects of prenatal low-protein and glucocorticoid exposure on postnatal angiotensin receptor expression. This study aimed to resolve this issue by comparing the effects of low-protein and glucocorticoid exposures on postnatal nephron number and angiotensin receptor expression. In addition, this study examined the modulation of prenatal treatment effects by postnatal inhibition of type 1 angiotensin receptor. The data demonstrates that whereas prenatal low-protein and glucocorticoid exposure have a similar effect in reducing nephron number, there are age- and gender-related differences in their effects on postnatal angiotensin receptor expression. In addition, this study provides novel evidence of a substantial upregulation of type 2 angiotensin receptor expression in low-protein- and glucocorticoid-exposed female offspring at 20 weeks of age, with implications for subsequent renal remodeling and function. Despite being targeted to the postnephrogenic period, inhibition of type 1 angiotensin receptor had an inhibitory effect on renal and somatic growth, additionally indicating its unsuitability during early life. (Hypertension. 2005;46:1374-1380.)

Key Words: hypertension ■ programming ■ gender ■ angiotensin receptor ■ nephron ■ rat

A range of environmental and lifestyle factors interact with the prevailing genotype to determine an individual’s risk of developing hypertension.1 However, in the last decade, it has become apparent that the environment encountered during early development also exerts a significant influence. Human epidemiological studies have demonstrated a relationship between parameters of fetal growth and the risk of developing hypertension,2,3 renal disease,4,5 and coronary heart disease.6,7 These observational studies are supported by a range of experimental models in which the cardiovascular and renal systems have been shown to be extremely sensitive to relatively mild shifts in maternal nutrition.8 These experimental models now provide a useful tool for examining the precise mechanisms involved.

Disturbance of the renin-angiotensin system (RAS) has been implicated in the nutritional programming of blood pressure. The RAS is a primary regulator of blood pressure, via its effects on vascular tone and fluid homeostasis,9 and is also critical for normal renal development.10,11 Disturbance of this system may, therefore, modulate adult blood pressure control both directly, via a long-term alteration in RAS activity, and indirectly, via disturbance of renal development and subsequent function. The feeding of a maternal low-protein (MLP) diet to rats during pregnancy suppresses the activity of the fetal intrarenal RAS12 and is associated with a reduced nephron complement13 and an accelerated progression toward glomerulosclerosis14 in the offspring. In contrast, the RAS is upregulated in MLP offspring in postnatal life,15 including both upregulation of the type 1 angiotensin receptor (AT1R), which mediates the classic pressor responses to Ang II,16,17 and downregulation of the counterregulatory type 2 receptor (AT2R).18–20 Consistent with these changes, increased angiotensin II (Ang II) sensitivity has been observed in MLP offspring at 4 and 7 weeks of age.18,19

Evidence suggests that the hypertensive effects of prenatal nutrient restriction are initiated by overexposure of the fetus to glucocorticoids during critical periods of development.8 Ordinarily, maternal steroids reaching the placenta are metabolized to inactive forms by the enzyme 11β-hydroxy-steroid dehydrogenase (11β-HSD). Decreased expression of placental 11β-HSD has been observed in nutritionally restricted rats21,22 and sheep.23,24 Administration of dexameth-

Received August 3, 2005; first decision August 29, 2005; revision accepted September 22, 2005.

From the Division of Nutritional Sciences, University of Nottingham, Loughborough, United Kingdom.

Correspondence to Simon C. Langley-Evans, Division of Nutritional Sciences, University of Nottingham, Sutton Bonington Campus, Loughborough, LE12 5RD, United Kingdom. E-mail simon.langley-evans@nottingham.ac.uk

Hypertension is available at http://www.hypertensionaha.org

DOI: 10.11611161101.HYP.000188702.96256.46
asone, a synthetic glucocorticoid not metabolized by 11β-HSD, or carbenoxolone, an inhibitor of 11β-HSD, during pregnancy replicates the effects of the MLP diet on nephron number and blood pressure.25,26 On the basis of this evidence, we hypothesized previously that programmed alterations in angiotensin receptor expression would also prove glucocorticoid dependent. However, our previous study20 indicated that prenatal dietary and glucocorticoid manipulation may exert conflicting effects on postnatal angiotensin receptor expression. Therefore, the primary aim of this study was to explore the hypothesis that prenatal carbenoxolone and low-protein treatments would have differential effects on postnatal renal angiotensin receptor expression. The permanency of these effects was assessed by maintaining a subset of offspring for 20 weeks of age. The interaction between nutritional and glucocorticoid treatments and the RAS was additionally investigated via inhibition of AT1R in the immediate postnatal period. Such treatment has been shown previously to prevent the hypertensive effect of a prenatal MLP diet, but to lead to morphological abnormalities if given during nephrogenesis.23 Therefore, the secondary aim of this study was to examine the modulation of prenatal carbenoxolone and low-protein treatments by AT1R inhibition once nephrogenesis is complete.

Methods

Animals

All of the animal procedures were performed in accordance with the Animals (Scientific Procedures) Act of 1986. Thirty-three virgin female Wistar rats (Harlan Ltd, Leicestershire, UK) were mated at weights between 250 and 300 g. On confirmation of mating, the rats were allocated to 1 of 3 treatment groups: control (n = 11), low-protein (MLP, n = 10), and carbenoxolone (CBX, n = 12). Control rats were fed a diet containing 20% protein (180 g casein/kg), and MLP rats were fed a diet containing 10% protein (90 g casein/kg). The full composition of the diets is published elsewhere.28 CBX rats were also fed the control diet but injected SC with CBX (12.5 mg/kg) for the last 7 days of pregnancy. CBX acts to inhibit 11β-HSD, increasing the passage of glucocorticoids across the placenta. CBX was administered at a dose shown to have no adverse effect on reproductive outcome.29 Control and MLP rats were injected with injection vehicle (saline) during the same period.

At birth (~22 days), all of the animals were transferred on to standard laboratory diet (B&K Universal Ltd), and the litters culled to a maximum of 8 pups to minimize variation in suckling nutrition. Between 2 and 4 weeks of age, the 3 treatment groups were additionally subdivided, with half of the litters from each prenatal treatment being administered L158-809, a specific AT1R inhibitor (kindly donated by Merck Sharpe and Dohme), through the drinking water. L158-809 was administered at a lower dose (25 mg/mL) than previously used with its predecessor, losartan (100 mg/L),29 because of evidence from pharmacological studies of its higher potency.31 All of the litters were weaned at 3 weeks of age. At 4 weeks of age, half of each litter (2 males and 2 females, where possible) were killed by CO2 asphyxia followed by cervical dislocation, and their kidneys were excised. The right kidney was frozen in liquid N2, before storage at −80°C before RT-PCR, and the left kidney was fixed in buffered formalin before nephron counting. The remainder of the animals were housed in single-sex groups and culled at 20 weeks using the same procedures.

Nephron Number

Nephron number was determined using a maceration method, as described previously.32 Triplicate aliquots were counted for each kidney. The coefficient of variation was 2.6%.

Angiotensin Receptor mRNA Expression

Total RNA was isolated from snap frozen kidneys using the TRIzol procedure (Invitrogen). The RNA was treated with DNase (Promega) and subjected to phenol-chloroform extraction and ethanol precipitation. Total RNA (0.5 μg) was reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Promega). Real-time PCR was performed using an ABI prism 7700 sequence detection system (Applied Biosystems). A template-specific primer pair and an oligonucleotide probe (VIC-Genosys) specific to AT1R, AT1B, and AT2R were designed using Primer Express, version 1.5 (Applied Biosystems). The full sequences of the primers and probes are published elsewhere.20 A negative template control, relative standard curve (prepared from pooled sample DNA), and quality control were included on every PCR run. All of the samples were normalized to β-actin expression.

Statistical Analysis

Results are presented as mean values with SEs. Statistical analysis was performed using SPSS version 11.0. The effects of prenatal treatment on parameters measured during pregnancy and at birth were compared by 1-way ANOVA. The effects of age, sex, prenatal treatment, and postnatal treatment on offspring parameters were assessed using a general linear model. Litter of origin was included in the model to adjust the outcome for the hierarchical variability derived from the same or different mother. Where there was a significant and independent effect of prenatal treatment, the least-significant difference post-hoc test was performed. Probability of <5% was taken as statistically significant.

Results

Maternal Data (Table 1)

Maternal weight at mating and weight gain during pregnancy did not differ between the prenatal treatment groups. Litter size, total litter weight, and mean birth weight were also unaffected by prenatal treatment.

Body and Kidney Weight (Table 2)

There was a significant interaction between the prenatal and postnatal treatment effects on offspring body weight at 4 weeks of age (P<0.001). CBX offspring were heavier at 4 weeks of age than their control and MLP counterparts, and postnatal L158-809 treatment reduced body weight in this group only. Actual kidney weights followed the same pattern as body weight. However, when adjusted for body weight, there just remained an overall effect of postnatal L158-809 treatment, which reduced kidney weight (P<0.001).

At 20 weeks of age, there was a significant, independent effect of postnatal L158-809 treatment in reducing body weight (P<0.01). Actual kidney weights were unaffected by prenatal or postnatal treatment. However, when adjusted for

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control (n=11)</th>
<th>MLP (n=10)</th>
<th>CBX (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal weight at mating (g)</td>
<td>261.8±7.6</td>
<td>273.7±7.5</td>
<td>267.4±9.5</td>
</tr>
<tr>
<td>Maternal weight gain (g)</td>
<td>168.6±6.5</td>
<td>154.0±10.4</td>
<td>158.0±5.1</td>
</tr>
<tr>
<td>Total birth weight (g)</td>
<td>79.7±4.7</td>
<td>73.6±5.1</td>
<td>78.6±2.7</td>
</tr>
<tr>
<td>Mean birth weight (g)</td>
<td>5.85±0.20</td>
<td>5.77±0.16</td>
<td>5.43±0.13</td>
</tr>
<tr>
<td>Litter no.</td>
<td>13.7±1.3</td>
<td>12.9±1.0</td>
<td>14.5±0.5</td>
</tr>
</tbody>
</table>

TABLE 1. Maternal Weight at Mating, Maternal Weight Gain During Pregnancy, Litter No., and Total and Mean Birth Weights in Control, MLP, and CBX Treatment Groups
There were significant, independent effects of prenatal treatment \((P < 0.01)\) and age \((P < 0.05)\) on renal AT1AR mRNA expression. The effect of age involved an upregulation of AT1AR expression at 20 compared with 4 weeks of age. Posthoc analysis showed that the prenatal effect involved a decrease in AT1AR expression in MLP offspring in comparison with both control \((P < 0.001)\) and CBX \((P < 0.01)\) offspring.

**AT1bR (Figure 3)**

There was a significant effect of age on AT1bR mRNA expression, with higher expression at 20 compared with 4 weeks of age \((P < 0.001)\). There was no significant effect of prenatal or postnatal treatment.

**AT2R (Figure 4)**

There were significant effects of prenatal \((P < 0.01)\) and postnatal \((P < 0.01)\) treatments on AT2R mRNA expression.

---

**Table 2. Body Weight and Kidney Weight in 4- and 20-Week-Old Rats from Control, MLP, or CBX Groups With or Without L158-809 Treatment in Early Postnatal Life**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sex</th>
<th>Control Water</th>
<th>MLP Water</th>
<th>CBX Water</th>
<th>Pre*post P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>4 weeks</td>
<td>20 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>M</td>
<td>M 103.5±2.3</td>
<td>M 587.9±20.4</td>
<td>M 807.9±20.4</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>94.5±1.4</td>
<td>130.5±6.4</td>
<td>133.0±8.6</td>
<td>NS</td>
</tr>
<tr>
<td>Kidney weight (g)</td>
<td>M</td>
<td>95.4±2.7</td>
<td>542.3±12.8</td>
<td>561.3±14.8</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>91.0±5.2</td>
<td>289.6±3.8</td>
<td>320.8±11.2</td>
<td>NS</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>M</td>
<td>108.6±3.1</td>
<td>527.5±18.4</td>
<td>527.5±18.4</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>97.6±2.8</td>
<td>299.0±7.0</td>
<td>284.6±7.9</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are the mean±SEM. The \(P\) values refer to the fixed effects of prenatal and postnatal treatments, sex, and the interaction between prenatal and postnatal treatments (pre*post). Body weight was entered as a covariate for analysis of kidney weights (fixed effect). NS indicates not significant.
The effect of prenatal treatment interacted with both age (P<0.01) and sex (P<0.01). As shown previously, exposure to MLP decreased AT2R expression at 4 weeks of age in female MLP offspring only. In contrast, at 20 weeks of age AT2R expression was increased in the MLP female offspring, whereas MLP male offspring showed no effect. Prenatal exposure to CBX increased AT2R expression at 4 weeks of age in both males and females in comparison to controls. This effect persisted to 20 weeks of age in the female CBX offspring only. The effect of postnatal treatment involved a decrease in AT2R mRNA expression in L158-809-treated offspring overall. There was an interaction between the effects of age and sex (P<0.001). At 4 weeks of age, expression of the AT2R was lower in males than females. Expression increased between 4 and 20 weeks in both males and females but to a greater extent in males.

**Discussion**

It has been proposed that disruption of the fetal and postnatal renal RAS may contribute to the programming of hypertension through receptor-mediated changes in Ang II activity. Additional evidence suggests that the programming of nephron deficit and hypertension is mediated by overexposure of the fetus to maternal glucocorticoids. This led us to hypothesize that changes in angiotensin receptor expression observed in response to a prenatal low-protein diet would also prove glucocorticoid dependent. However, our previous study showed the programming of AT2R mRNA expression in 4-week-old female offspring to be independent of glucocorticoid exposure. Furthermore, prenatal glucocorticoid and low-protein exposures appeared to have conflicting effects on postnatal AT2R mRNA expression. The primary aim of this study was to resolve this issue by comparing the effects of prenatal low-protein and CBX treatments on postnatal nephron complement and angiotensin receptor expression and to assess the permanency of the effects by examining a subset of animals at 20 weeks of age. The secondary aim was to examine the modulation of these effects by postnatal inhibition of AT2R. The data demonstrates that, whereas prenatal low-protein and CBX exposures have a similar effect in reducing the nephron number, there are age- and gender-related differences in their effects on postnatal angiotensin receptor expression. In addition, this study provides novel evidence of a substantial upregulation of AT2R expression in female MLP and CBX offspring at 20 weeks of age, which is secondary to the onset of hypertension and prevented by postnatal AT2R inhibition.

The RAS is a primary regulator of blood pressure via its effects on vascular tone and fluid homeostasis. AT2R mediates the classic pressor responses to Ang II, which include vasoconstriction, aldosterone and vasopressin release, and renal tubular sodium reabsorption. AT2R is thought to be primarily involved in the functioning and development of the fetal kidney. However, transgenic and selective inhibition studies show that, in adult life, AT2R acts to oppose the AT1R-mediated effects through counter-regulatory vasodilation. Kidneys from 4-week-old MLP offspring exhibit both increased protein expression of AT2R and decreased mRNA and protein expression of AT1R. Consistent with this, an increased pressor response and a greater increase in glomerular filtration rate in response to Ang II have been observed in MLP offspring. The current study agreed with our previous work by demonstrating a reduction in AT2R mRNA expression in 4-week-old female MLP offspring. In addition, the 4-week data supported our primary hypothesis that prenatal low-protein and glucocorticoid exposures would have opposing effects on postnatal AT2R mRNA expression, because female CBX offspring exhibited increased AT2R mRNA expression, in direct contrast to their low-protein counterparts. However, our primary hypothesis was not fully supported, because the extension of our studies to 20 weeks...
showed the 4-week effect to be transient, with both MLP and CBX exposure programming an increase in renal AT₂R mRNA expression in 20-week-old female offspring. This suggests that the glucocorticoid and protein-restriction treatments both lead to AT₂R upregulation in the long term but that the timing of onset differs between the 2 models used. Although the apparently transient reduction in AT₁R expression in 4-week MLP offspring may contribute to the initial renal impairment, it does not appear to contribute to the maintenance of hypertension.

Although usually expressed at low levels in adult life, AT₂R is known to be upregulated in response to renal injury, promoting remodeling via apoptosis and proliferation. Upregulation of renal AT₁R mRNA and protein expression has been observed in response to partial renal ablation, and postsurgical treatment with the specific AT₂R inhibitor PD123319 potentiated the subsequent development of hypertension in this model, indicating a protective role. In the current study, the upregulation of AT₂R mRNA expression in female offspring is secondary to the onset of hypertension consistently observed in this model. On the basis of this evidence, we suggest that the increase in AT₂R mRNA expression observed at 20 weeks of age constitutes a counter-regulatory response, acting to protect the kidney from the ongoing pathology. Additional study is required to test this novel hypothesis and to ascertain the functional and physiological significance of the substantial upregulation of AT₂R mRNA expression. The earlier emergence of AT₂R upregulation in CBX offspring may signify the prenatal CBX treatment as more severe in terms of renal injury than the MLP treatment. The 2 treatments reduced the nephron number to a similar degree (Figure 1), but a more detailed histological assessment of kidney damage is warranted.

Of particular interest is the insensitivity of AT₂R mRNA expression in male offspring to prenatal MLP exposure. In this and our previous study, AT₁R mRNA expression in control animals is significantly higher in females than males. The postinjury increase in AT₁R expression observed in the renal ablation model proved to be autonomously regulated. Thus, the higher basal level of renal AT₂R expression in the females may in itself underlie the gender-specific response. The renal ablation model did, however, demonstrate an AT₂R response to renal injury in male rats, perhaps reflecting the increased severity of renal injury in the ablation model compared with the MLP programming model or differences in the age and breed of rat used. There is much evidence from both animal and human studies to suggest that the progression of renal disease and hypertension is attenuated in females. Hypertension progresses more rapidly and severely in males than females in a number of commonly used rodent models, and male rats have been shown to be more vulnerable to the development of renal injury after subtotal nephrectomy and 2-kidney 1-clip. Although both sexes are susceptible to programming stimuli during pregnancy, studies that demonstrate gender differences in the timing of onset and severity of hypertension consistently show the effects to favor female rather than male offspring. Lower basal AT₂R mRNA expression and attenuation of upregulation, as observed in male MLP offspring, may contribute to the increased susceptibility to and faster progression toward renal disease and hypertension observed in male subjects. Additional studies involving the use of specific receptor antagonists together with detailed examination of renal injury and remodeling are required to test this novel hypothesis. Although a high degree of compliance has been observed between mRNA and protein expression of AT₂R (N. Ashton, S. McMullen, and S.C. Langley-Evans, unpublished observations, 2004), we would also wish to confirm these findings at the level of protein expression.

We had previously shown no change in AT₁R or AT₂R mRNA expression in 4-week-old MLP offspring despite others showing upregulation of protein expression, initially suggesting interference at the post-transcriptional level only. However, preliminary protein analysis of kidney samples from our MLP model indicate that protein expression is not increased either (N. Ashton, S. McMullen, and S.C. Langley-Evans, unpublished observations, 2004). The current study shows an overall downregulatory effect of the low-protein diet on AT₂R mRNA expression across the 2 time points. This study used a larger number of animals than our previous to assess outcome at 2 postnatal time points and was, therefore, more highly powered to detect those main effects that did not interact with age. This is likely to explain why the small overall decrease in AT₂R mRNA expression did not prove significant in our studies limited to 4-week-old offspring. The lack of AT₁R upregulation in the MLP offspring of this and our previous studies does not support this mechanism as an underlying cause of their hypertension in the long term.

Inhibition of AT₁R in the immediate postnatal period has been shown to prevent the hypertensive effect of a prenatal low-protein diet in the short term but to lead to morphological abnormalities and secondary hypertension in the long term. Nephrogenesis in the rat is not completed until 10 days postnatally, and it has been proposed that the detrimental effect of AT₁R inhibition was limited to the period of nephrogenesis. The secondary aim of this study was to examine the modulation of CBX and low-protein effects by AT₁R inhibition once nephrogenesis was complete, with the hypothesis that this would be a “safe” window for intervention. However, in control animals, postnatal AT₁R inhibition reduced the nephron number by the same degree as prenatal MLP and CBX treatments (Figure 1). Because nephrogenesis was complete at the time of intervention, it must be concluded that the RAS plays an additional role in renal tissue remodeling and maturation in the postnephrogenic period, with inhibition promoting nephron injury and loss. This suggests that the period at which it should be contraindicated extends further into early life than was previously thought. Interestingly, AT₂R inhibition also prevented the upregulation of AT₁R in female offspring, and this may additionally exacerbate the renal damage in the long term. 158-809 also had an inhibitory effect on somatic and renal growth, although the effect was transient with respect to the kidney. This supports previous studies indicating that the somatic effects of Ang II are mediated by AT₁R and adds additional weight to its unsuitability as a hypertensive treatment in early life.
Perspectives
The RAS undoubtedly plays a central role at many stages in the life cycle of the kidney, through regulating development, maturation, and function. The evidence for its role in the development and pathogenesis of programmed hypertension is also strong, but the complex interactions with glucocorticoid exposure, age, and gender are only just becoming clear. This study adds to previous work by our peers and us by unravelling these interactions and refining the mechanistic theory. The evidence of the sex specificity of these interactions highlights the need to assess the impact of gender in future studies examining the mechanistic aspects of programming. It is becoming clear that the factors important in mediating the prenatal origins of adult hypertension may differ from those important in regulating the severity and progression of subsequent disease. The substantial upregulation of AT1R mRNA expression secondary to the pro- grammed phenotype in female offspring is of particular significance of such upregulation.

Acknowledgments
This study was funded by the British Heart Foundation and by the European Union EARNest project. The authors acknowledge the technical assistance of Richard Plant.

References


Sex-Specific Effects of Prenatal Low-Protein and Carbenoxolone Exposure on Renal Angiotensin Receptor Expression in Rats
Sarah McMullen and Simon C. Langley-Evans

Hypertension. 2005;46:1374-1380; originally published online October 17, 2005;
doi: 10.1161/01.HYP.0000188702.96256.46
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/46/6/1374

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/